TrialDrugs2026

Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes.

John A Hey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.